NOTE: All in-article links open in a new tab.

Medicare Coverage Requirements: Cochlear Implants, Lung Cancer Screening and Lumbar Decompression

Published on 

Monday, February 9, 2015

No items found.

I try to write an article for the second Wednesday of the month newsletter about Medicare coverage policies and an article about Medicare contractors’ medical reviews for the third Wednesday. You may have noticed however, that these two topics are often intermingled. It brings to mind the age-old riddle – which came first, the chicken or the egg? Is a particular medical review based on the guidelines of a coverage policy or did the results of a review identify the need to develop a coverage policy? Actually, both scenarios occur, so sometimes it’s the chicken and sometimes the egg!

The December 2014 OIG Compliance Review of Ochsner Medical Center included the findings of a new issue not addressed in previous OIG compliance reviews. The issue is certain cochlear implant services did not meet the medical necessity requirements of the National Coverage Determination (NCD 50.3). As often is the case, the NCD requirements are extremely detailed. Cochlear implants are covered if the following conditions are met:

  • Diagnosis of bilateral moderate-to-profound sensorineural hearing impairment
  • Limited benefit from amplification (test scores of less than or equal to 40%)
  • Cognitive ability to use auditory clues and a willingness to undergo an extended program of rehabilitation;
  • Freedom from middle ear infection, an accessible cochlear lumen that is structurally suited to implantation, and freedom from lesions in the auditory nerve and acoustic areas of the central nervous system;
  • No contraindications to surgery; and
  • The device must be used in accordance with Food and Drug Administration (FDA)-approved labeling.
  • Clinical trial services are covered for individuals meeting the selection guidelines above and with hearing test scores of greater than 40% and less than or equal to 60%.

The key to coverage criteria is not only must it be met, but it must be documented in the medical record in order to support that the service met Medicare’s coverage requirements. The OIG review found one patient whose hearing test score was 42% and one patient without a documented hearing test. These two errors resulted in an overpayment of over $56,000.

Another recent coverage decision with numerous detailed requirements is the Final Decision Memo for Lung Cancer Screening with Low Dose CT. This decision memo was released last Thursday (February 5, 2015). The eligibility criteria for screening include:

  • Current smoker or one who has quit within the past 15 years
  • Asymptomatic (no signs or symptoms of lung cancer)
  • Age 55-77
  • A 30-pack years smoking history (one pack-year = smoking one pack per day for one year)

In addition to the eligibility criteria, the decision memo lists detailed requirements for the order for low dose CT, including what it must contain, when it can be written, and the requirements for what a lung cancer counseling visit must include. There are also required criteria for the reading radiologist and the imaging facility. The details of the policy are quite extensive. Remember - although the effective date of the policy is February 5, 2015, it may be a while before CMS issues the official NCD and provides billing instructions. Medicare Administrative Contractors may not be ready to process these claims until the effective date of the forthcoming manualization of this decision.

One last update concerning NCDs - MLN Matters Article MM8954 provides guidance on the use of new HCPCS code G0276 for (Percutaneous Image-guided Lumbar Decompression (PILD) for Lumbar Spinal Stenosis (LSS)). Per this update, G0276 is to be used on and after January 1, 2015 only if the clinical trial is blinded, randomized, and controlled, and contains a placebo procedure control arm. Use procedure code 0275T for clinical trials for all PILD for LSS services for dates of service prior to January 1, 2015 and after January 1, 2015 for services not meeting the criteria for G0276.

So remember – after the chicken comes the egg – or is it, after the egg, comes the chicken?!? Whichever, but if there is a coverage policy, there may be a medical review in your future – so make sure you follow the criteria for cochlear implants, low dose CT lung cancer screening, and PILD for LSS and of course – document, document, document!

Updates of Local Coverage Determinations for last month include:

Cahaba J10 Coverage Updates

IDTitleComment Start DateComment End DateFinalStatus
DL35920Medicine: Quantitative Drug Testing3/25/20155/8/2015NoDraft
DL35624Surgery: Fusion for Degenerative Joint Disease of the Lumbar Spine3/25/20155/8/2015NoDraft

Palmetto GBA Coverage Updates

IDTitleComment Start DateComment End DateFinalStatus
DL35896MolDX: Comprehensive Genomic Profiling for Non-Small Cell Lung Cancer2/10/20153/27/2015NoDraft
DL35912MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)2/10/20153/27/2015NoDraft
DL35827MolDX: Molecular RBC Phenotyping2/10/20153/27/2015NoDraft
DL33050Total Joint Arthroplasty2/10/20153/26/2015NoDraft
IDTitleEffective DateRevision Effective DateEnd DateLast UpdatedStatus
A54036Infrared Coagulation (IRC) of Hemorrhoids Supplemental Instructions Article2/5/2015N/AN/A1/27/2015New
A53982Percutaneous Ventricular Assist Device1/15/2015N/AN/A1/7/2015New

Novitas JH & JL Coverage Updates

IDTitleDateDateFinalStatus
DL35759Allergen Immunotherapy1/15/20153/5/2015NoDraft
DL35771Allergy Testing1/15/20153/5/2015NoDraft
DL35771Ambulance Services (Ground Ambulance)1/15/20153/5/2015NoDraft
DL35771Autonomic Function Tests1/15/20153/5/2015NoDraft
DL33638Biomarkers Overview1/29/20153/19/2015NoDraft
DL27487Debridement of Mycotic Nails1/15/20153/5/2015NoDraft
DL31399Magnetic Resonance Angiography (MRA)1/15/20153/5/2015NoDraft
DL27532Surgical Treatment of Nails1/15/20153/5/2015NoDraft
DL35823Tear Testing for Dry Eyes1/15/20153/5/2015NoDraft
DL32767Vestibular and Audiologic Function Studies1/15/20153/5/2015NoDraft

First Coast JN Coverage Updates

IDTitleEffective DateRevision Effective DateEnd DateLast UpdatedStatus
L28777Alemtuzumab (Campath®)2/16/20091/11/20111/1/20151/1/2015Retired
Article Author: Debbie Rubio, BS MT (ASCP)
Debbie Rubio, BS MT (ASCP), was the Manager of Regulatory Affairs and Compliance at Medical Management Plus, Inc. Debbie has over twenty-seven years of experience in healthcare including nine years as the Clinical Compliance Coordinator at a large multi-facility health system. In her current position, Debbie monitors, interprets and communicates current and upcoming regulatory and compliance issues as they relate to specific entities concerning Medicare and other payers.

This material was compiled to share information.  MMP, Inc. is not offering legal advice. Every reasonable effort has been taken to ensure the information is accurate and useful.